tiprankstipranks
Pulmatrix (PULM)
:PULM

Pulmatrix (PULM) AI Stock Analysis

Compare
778 Followers

Top Page

PU

Pulmatrix

(NASDAQ:PULM)

56Neutral
Pulmatrix's overall score is driven by its strong technical indicators and the positive impact of the strategic merger with Cullgen. However, the company's financial performance, particularly its profitability and cash flow challenges, significantly weigh down the score. The negative valuation metrics also contribute to a lower overall score, despite the potential long-term benefits of the merger.

Pulmatrix (PULM) vs. S&P 500 (SPY)

Pulmatrix Business Overview & Revenue Model

Company DescriptionPulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on the development of inhaled therapies to address serious pulmonary diseases. Operating within the pharmaceuticals and biotechnology sectors, the company employs its proprietary iSPERSE technology to design and develop novel inhalation therapies targeting respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and other lung-related conditions.
How the Company Makes MoneyPulmatrix generates revenue primarily through the development and commercialization of its inhaled therapeutic products. The company earns money through strategic partnerships and collaborations with other pharmaceutical companies, which provide funding for research and development, as well as potential milestone and royalty payments upon successful commercialization of its products. Additionally, Pulmatrix may receive revenue from licensing its iSPERSE technology to third parties for their own product development. The company's financial success heavily relies on the successful progression of its drug candidates through clinical trials and eventual market approval.

Pulmatrix Financial Statement Overview

Summary
Pulmatrix shows growth in revenue but struggles with profitability and cash flow management. The company's strong equity position offsets some financial risks, but continuous operational losses and negative cash flows highlight the need for strategic adjustments to improve financial health.
Income Statement
35
Negative
Pulmatrix's revenue has increased significantly in the TTM, showing a positive revenue growth trend from the previous annual period. However, profitability remains a concern as the company is operating at a net loss, with negative EBIT and EBITDA margins indicating financial challenges in managing operational costs.
Balance Sheet
58
Neutral
The company maintains a strong equity position with no debt in the latest period, reflected in a low debt-to-equity ratio and a high equity ratio. However, a declining trend in stockholders' equity over the past years indicates potential sustainability concerns.
Cash Flow
40
Negative
Pulmatrix's cash flow situation is under pressure with negative free cash flow and operating cash flow in the TTM. The lack of positive cash flow generation indicates ongoing challenges in funding operations without external financing.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
4.02M7.30M6.07M5.17M12.63M7.91M
Gross Profit
-11.46M-8.22M4.53M-10.21M12.63M-4.93M
EBIT
-21.75M-14.74M-18.95M-20.17M-573.00K-20.69M
EBITDA
-17.02M-13.27M-17.40M-15.35M-9.86M-13.24M
Net Income Common Stockholders
-21.78M-14.12M-18.73M-22.50M-28.52M-20.39M
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.56M19.17M35.63M53.84M31.66M23.44M
Total Assets
14.72M33.96M40.95M58.82M38.17M36.10M
Total Debt
0.008.76M857.00K2.29M1.74M675.00K
Net Debt
-2.56M-10.42M-34.77M-51.55M-29.91M-22.77M
Total Liabilities
2.88M15.96M9.84M11.37M15.03M25.08M
Stockholders Equity
11.84M18.00M31.11M47.45M23.14M11.02M
Cash FlowFree Cash Flow
-18.62M-16.66M-19.44M-19.87M-12.76M3.17M
Operating Cash Flow
-18.41M-15.98M-19.36M-19.73M-12.48M3.23M
Investing Cash Flow
-203.00K-676.00K-86.00K-144.00K-281.00K-58.00K
Financing Cash Flow
6.04M53.00K1.23M43.48M20.98M17.70M

Pulmatrix Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.11
Price Trends
50DMA
7.28
Positive
100DMA
5.85
Positive
200DMA
3.95
Positive
Market Momentum
MACD
0.01
Positive
RSI
54.52
Neutral
STOCH
49.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PULM, the sentiment is Positive. The current price of 8.11 is above the 20-day moving average (MA) of 7.96, above the 50-day MA of 7.28, and above the 200-day MA of 3.95, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 54.52 is Neutral, neither overbought nor oversold. The STOCH value of 49.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PULM.

Pulmatrix Risk Analysis

Pulmatrix disclosed 45 risk factors in its most recent earnings report. Pulmatrix reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pulmatrix Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$1.10B83.223.42%14.88%-86.70%
64
Neutral
$125.40B-3.15%11.64%-114.72%
60
Neutral
$1.34B-23.01%168.06%44.66%
56
Neutral
$26.99M-62.70%47.05%40.66%
53
Neutral
$421.09M91.25%-12.26%32.86%
49
Neutral
$6.90B0.02-54.05%2.46%24.91%-3.14%
46
Neutral
$249.73M-33.88%-22.66%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PULM
Pulmatrix
8.11
6.37
366.09%
INVA
Innoviva
17.41
2.69
18.27%
VRTX
Vertex Pharmaceuticals
495.42
86.65
21.20%
AKBA
Akebia Therapeutics
1.93
0.56
40.88%
ARDX
Ardelyx
5.44
-2.59
-32.25%
AVIR
Atea Pharmaceuticals
3.10
-0.75
-19.48%

Pulmatrix Corporate Events

M&A TransactionsDividendsBusiness Operations and Strategy
Pulmatrix and Cullgen Announce Strategic Merger Agreement
Positive
Nov 13, 2024

Pulmatrix and Cullgen have announced a merger to form a Nasdaq-listed entity focused on targeted protein degradation, with promising clinical trials in cancer and pain management underway. The merger, expected to finalize by March 2025, will see Cullgen shareholders owning the majority stake, while Pulmatrix plans to distribute a cash dividend to its shareholders. This strategic move aims to enhance growth through Cullgen’s innovative drug development platform, with the combined company holding approximately $65 million in funds to support multiple clinical milestones.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.